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Objective To investigate patient factors predictive of gamma glutamyltransferase (GGT) normalization following
ursodeoxycholic acid (UDCA) therapy in children with primary sclerosing cholangitis.
Study design We retrospectively reviewed patient records at 46 centers. We included patients with a baseline
serum GGT level ≥50 IU/L at diagnosis of primary sclerosing cholangitis who initiated UDCA therapy within 1 month
and continued therapy for at least 1 year. We defined “normalization” as a GGT level <50 IU/L without experiencing
portal hypertensive or dominant stricture events, liver transplantation, or death during the first year.
Results We identified 263 patients, median age 12.1 years at diagnosis, treated with UDCA at a median dose of
15mg/kg/d. Normalization occurred in 46%. Patients with normalization had a lower prevalence of Crohn’s disease,From the 1Department of Pediatrics, University of Utah,
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tio index, greater platelet count, and greater serum albumin level at diag-
nosis. The 5-year survival with native liver was 99% in those patients who
achieved normalization vs 77% in those who did not.
Conclusions Less than one-half of the patients treated with UDCA
have a complete GGT normalization in the first year after diagnosis, but
this subset of patients has a favorable 5-year outcome. Normalization is
less likely in patients with a Crohn’s disease phenotype or a laboratory
profile suggestive of more advanced hepatobiliary fibrosis. Patients
who do not achieve normalization could reasonably stop UDCA, as
they are likely not receiving clinical benefit. Alternative treatments with
improved efficacy are needed, particularly for patients with
already-advanced disease. (J Pediatr 2019;-:1-5).
P
rimary sclerosing cholangitis (PSC) is a rare cholestatic liver disease
characterized by progressive destruction of the bile ducts.1 Within
10 years of diagnosis, 30% of children with PSC will require liver
transplantation and 50% of children will develop complications, including
biliary stricturing and portal hypertension.2 To date, there is no medical
intervention proven to prolong patient survival.3 PSC is recognized as one the
largest unmet needs in hepatology.4
Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with hepatobiliary
cytoprotective and immune-modulating effects.5-7 The role of UDCA in
modifying disease behavior in PSC and prolonging patient survival is
controversial. UDCA has not been shown to improve patient survival in adultresponsibility of the authors and does not necessarily
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APRI Aspartate aminotransferase to platelet ratio index
AST Aspartate aminotransferase
GGT Gamma glutamyl transferase
IBD Inflammatory bowel disease
PSC Primary sclerosing cholangitis
UDCA Ursodeoxycholic acid
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume-  - 2019clinical trials.8-12 Given the unclear benefit, as well as a pos-
sibility that greater doses of UDCA may cause harm,12 the
current practice guideline of the American Association of
the Study of Liver Diseases recommends against the use of
UDCA in adults with PSC.13 There are no formal guidelines
for the use of UDCA in children with PSC.
A subset of adults normalize serum alkaline phosphatase
levels during UDCA therapy and have improved survival
compared with those with persistently elevated levels.14-16
We showed an analogous effect in children with PSC using
gamma glutamyl transferase (GGT) as a biomarker.17
Children whose GGT declined to <50 IU/L at 1 year after
PSC diagnosis had favorable long-term outcomes. Untreated
patients who spontaneously normalized serum GGT levels
also had good outcomes. The proportion of patients who
achieved GGT normalization was greater in those treated
with UDCA; however, with an approximate number needed
to treat of 4 patients to achieve 1 normalization that would
not have occurred on its own. Thus, there appears to be a
subgroup of children treated with UDCA who have a
favorable response.
UDCA is the most common medication used in children
with PSC, with more than 80% currently receiving
long-term therapy.2,18 More data are needed to better define
which patients may be receiving a clinical benefit from
UDCA therapy. There are presently no predictors of which
patients will respond. The aim of this study was to identify
baseline differences between children with complete vs
incomplete biochemical normalization on UDCA.
Methods
The Pediatric PSC Consortium is an active research
collaboration that includes 49 centers in Europe,
North America, the Middle East, and Asia. We retrospectively
reviewedmedical records on all known patients with PSCwith
disease onset before 18 years of age at each institution, as pre-
viously described.2 For each patient, we collected data on basic
demographics and diagnostic cholangiography and histopa-
thology studies. We collected laboratory data at liver disease
diagnosis and approximately 1 year later (within 46-58 weeks
after diagnosis). To account for thewide range of normal alka-
line phosphatase values in children at various ages due to bone
turnover and growth, we normalized all values for age using
Mayo Medical Laboratories reference values.19
The diagnosis of PSC required elevated hepatobiliary
inflammatory markers (GGT or aspartate aminotransferase
[AST] or alanine aminotransferase) and/or bilirubin. When
characteristic changes on cholangiography were seen,
large-duct PSC was diagnosed. When cholangiography was
normal but liver histopathology showed typical changes,
small-duct PSC was diagnosed.13 Cases of sclerosing
cholangitis secondary to any other cause were excluded.
Autoimmune hepatitis was diagnosed in patients who met
the simplified autoimmune hepatitis criteria, which have
been validated in children,20 based on histopathology,2positive autoantibodies, elevated serum globulins, and
exclusion of viral hepatitis. We documented the presence
and type of associated inflammatory bowel disease (IBD).
We created a retrospective cohort of all patients followed
from date of PSC diagnosis to the date of several clinical
endpoints: (1) the development of portal hypertensive
complications (ascites, hepatic encephalopathy, or
esophageal varices with or without bleeding); (2) biliary
complications (a clinical picture of biliary obstruction as
evidenced by a biliary stricture requiring an intervention in
the form of endoscopic or percutaneous stenting, balloon
dilation, or drainage); (3) cholangiocarcinoma; (4) liver
transplantation; or (5) death from liver disease. Survival
free of any of these endpoints was termed event-free survival.
Patients were censored at the date of last known follow-up.
We excluded patients who presented with portal
hypertensive or biliary complications within 3 months of
PSC diagnosis from this analysis, because their
baseline laboratory studies were likely reflective of the
outcomes of interest already being present. Data were
abstracted and deidentified at local study sites and reviewed
and stored centrally. Study data were collected and managed
using REDCap (Research Electronic Data Capture)
electronic data capture tools hosted at the University of
Utah.21
In this analysis, we included patients with baseline serum
GGT levels >50 IU/L who started UDCA within 1 month
of PSC diagnosis and continued taking it for at least 1 year.
We defined “normalization” as a decline in GGT to ≤50
IU/L without experiencing clinical endpoints during the first
year. The threshold of 50 IU/L for GGT represents 1-2 times
the upper limit of normal for most noninfant pediatric age
groups at most laboratories and was validated as an endpoint
in our previous study.17We compared baseline demographic,
phenotypic, and laboratory data between these 2 groups. We
assessed differences in the change in laboratory studies
between diagnosis and at 1 year. We compared
transplant-free survival after 1 year between groups.
The Wilcoxon rank sum and c2 tests were used to assess
differences between groups. We used the Kaplan–Meier
method to calculate annual outcome probabilities. The
log-rank test assessed survival differences between groups.
Logistic regression was used to assess the association between
baseline predictor variables and treatment success or failure.
Variables with P value < .1 in univariate analyses were
included in a multivariate model. The model was optimized
using variance inflation factor diagnostics, removing any
collinear variables. Calculations were done using Stata
version 15 (StataCorp, College Station, Texas). All research
work was approved by the institutional review board of
each participating center.
Results
We identified 344 patients with a serum GGT level >50 IU/L
at diagnosis who had laboratory data 1 year later. WeDeneau et al
Table I. Baseline phenotypic and laboratory data
Normalization
N = 122
Non-normalization
N = 141
P
value
Age, y 12.0 [7.8-15] 12.4 [8.6-15] .416
Sex (% male) 60% 60% .941
Ulcerative colitis
(% with)
74% 59% .012
Crohn’s disease
(% with)
10% 18% .017
No IBD (% with) 16% 23% .203
Autoimmune hepatitis 39% 39% .955
Large-duct phenotype73% 76% .586
Hemoglobin, g/dL 12.4 [11.5-13.2] 12.1 [11-13.4] .137
Platelet count, k/mL 325 [260-438] 298 [196-375] <.001
INR 1.1 [1-1.2] 1.1 [1-1.2] .331
ALT, U/L 167 [87-297] 146 [87-229] .278
AST, U/L 125 [71-226] 140 [78-192] .697
ALP, U/L 406 [281-720] 448 [275-717] .918
ALP ( ULN) 1.0 [0.7-1.6] 1.0 [0.6-1.5] .461
GGT, U/L 290 [148-427] 290 [192-465] .158
Total bilirubin, mg/dL 0.7 [0.4-1] 0.9 [0.5-1.6] .002
Albumin, g/L 4.1 [3.7-4.5] 3.9 [3.6-4.3] .008
APRI 0.9 [0.5-1.9] 1.3 [0.7-2.3] .023
ALP, alkaline phosphatase; ALT, alanine aminotransferase; INR, international normalized ratio;
ULN, upper limit of normal.
Values are represented as median [interquartile range]. Values in bold are statistically
significant.
Logrank P < .001
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Figure 1. Long-term survival with native liver in patients
treated with UDCA.
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and 18 patients with clinical complications at or within
3 months after diagnosis. The remaining 263 patients (60%
male, median age 12.1 years old, median GGT 290 [IQR
163-431]) were followed for a median of 5.4 years with a total
of 1736 person-years of observation. Themedian UDCA dose
administered was 15 mg/kg/d (IQR 15-19).
Serum GGT normalization occurred in 46% (122/263) of
patients. In the remainder, non-normalization occurred in
16% (23/141) due to occurrence of clinical events and in
84% due to persistently elevated GGT at 1 year. Patients
with normalization vs non-normalization had similar PSC
phenotypes. At diagnosis, however, the response group hadTable II. Change in biochemistry over 1 year of UDCA
treatment
Normalization
n = 122
Non-normalization
n = 141
P
value
Hemoglobin,
g/dL
+0.8 [–0.4 to +1.6] +0.6 [–0.4 to +1.5] .382
Platelet count,
k/mL
-34 [–114 to +5] -32 [–87 to +22] .132
INR 0 [–0.1 to +0.1] 0 [–0.1 to +0.2] .600
ALT, U/L –141 [–266 to -59] –70 [–165 to +3] <.001
AST, U/L -92 [–197 to -40] -62 [–151 to -7] <.001
ALP, U/L –278 [–411 to +2] –129 [–618 to +80] <.001
ALP ( ULN) –0.6 [–1.3 to –0.2] –0.3 [–0.9 to 0] <.001
GGT, U/L –258 [–406 to –127] –142 [–271 to –42] <.001
Total bilirubin,
mg/dL
–0 [–0.4 to +0.2] +0.1 [–0.7 to +0.2] .567
Albumin, g/L +0.2 [–0.1 to +0.6] +0.1 [–0.3 to +0.4] .038
APRI -0.7 [–1.6 to -0.2] -0.4 [–1.3 to 0] .023
Values are represented as median [interquartile range]. Values in bold are statistically
significant.
Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing C
Normalization and Favorable Clinical Coursea lower prevalence of Crohn’s disease, lower total bilirubin,
lower aspartate aminotransferase to platelet ratio index
(APRI), greater platelet count, and greater serum albumin
(Table I). In addition to the primary endpoint of GGT
reduction, the normalization group experienced larger
improvements in alanine aminotransferase, AST, alkaline
phosphatase, and APRI compared with those with
non-normalization in the year after PSC diagnosis (Table II).
The presence or absence of a Crohn’s disease IBD
phenotype, as well as baseline platelet count, total bilirubin,
and albumin at diagnosis showed significant univariate
correlation with treatment response (Table III; available at
www.jpeds.com). After regression diagnostics including all
variables with P < .10 in univariate analysis, hemoglobin
was removed for excessive covariance. In the final
multivariate model, a Crohn’s phenotype decreased the
odds of normalization. Increased platelet count and serum
albumin significantly increased the odds of a normalization
(Table IV; available at www.jpeds.com).
Long-term survival with native liver after 1 year was better
in the normalization group than the incomplete response
group (Figure 1). Following the first year of UDCA
treatment, the annual event rate (deaths or liver transplants
per group per year) was 0.7%/year in the normalization
group vs 4.3%/year in the non-normalization group,
log-rank P < .001. The 5-year survival with native liver was
99% (95% CI 94-100) in those with normalization,
compared with 77% (95% CI 68-84) in those who did not
achieve normalization, P < .001.
Among those who did not normalize GGT on UDCA who
did not experience an adverse clinical event within the first
year, event-free survival from years 1 to 6 was different based
on the percentage GGT reduction achieved by 1 year
(Figure 2). There was a trend toward the best event-free
survival for patients with the largest relative GGT
reductions between diagnosis and year 1. Those with a
>75% reduction in GGT, compared with a <25% reductionholangitis: Predictors of Gamma Glutamyltransferase 3
**
* Logrank P = .055
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Figure 2. Event-free survival after 1 year in patients with
incomplete biochemical response to UDCA, stratified by
percentage reduction in GGT from baseline.
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5 years, P = .055.
Discussion
Although only a minority of children experience
normalization of their serum GGT level in response to
UDCA therapy, those who do show a decreased likelihood
of liver transplant or death during follow-up. We identified
clinically relevant patient factors at baseline associated with
non-normalization on UDCA treatment, including a Crohn’s
disease IBD phenotype, relative thrombocytopenia,
hypoalbuminemia, or hyperbilirubinemia, and increased
APRI, a surrogate marker of fibrosis.
The 46% normalization rate observed in this study is
similar to a 41% biochemical response seen in an adult
prospective trial of UDCA.15 In our pediatric cohort,
outcomes were best in those with GGT <50 IU/L at 1 year
after diagnosis. Even among those with GGT ≥50 IU/L at
1 year, outcomes were better with progressively larger
reductions in GGT between diagnosis and 1 year. Those
who had a reduction in GGT of >75% had nearly the same
long-term survival as those with GGT <50 IU/L at 1 year.
These data further support the utility of GGT reduction as
a candidate surrogate endpoint for future clinical trials.
Clinically, children with PSC on long-term UDCA who
have not had a >75% reduction in GGT or complete
normalization of GGT can stop the medicine, as they are
unlikely to be receiving a clinical benefit and could minimize
unnecessary drug exposure.
Of note, we do not know how many of the patients treated
with UDCA would have had spontaneous GGT
normalization and no adverse liver events without UDCA
therapy. We previously showed that nearly one-third of4children who are UDCA-na€ıve have spontaneous GGT
normalization by 1 year. These untreated patients’
long-term survival outcomes are indistinguishable from
patients treated with UDCA with GGT normalization.17 A
larger proportion of patients treated with UDCA achieved
GGT normalization, however. The number of patients with
PSC who would need to be treated with UDCA to achieve
1 case of GGT normalization that would not have occurred
spontaneously without treatment was approximately 4
(number needed to treat = 4).
A recent clinical trial evaluated the impact of UDCA
withdrawal from children with PSC who had been on chronic
therapy with normal liver biochemistries. Upon complete
withdrawal of the medication for 12 weeks, one-third of
patients maintained serum GGT levels <29 IU/L.22 Whether
the one-third of patients who may have spontaneously
normalized GGT and the one-third of patients who
maintained a normal GGT on complete withdrawal of
UDCA represent the same group is speculative, but it is likely
that a large proportion of children on chronic UDCA are
receiving no clinical benefit. More data on the natural history
of GGT in patients exposed and not exposed to UDCAwithin
the first 3-6 months after diagnosis are needed to determine
the optimal length of a trial of UDCA therapy.
Liver disease phenotype was not associated with
normalization: patients with large-and small-duct disease
had equivalent normalization rates, and the presence of
autoimmune hepatitis overlap features did not affect
outcome. Similarly, no phenotypic differences were observed
in UDCA complete vs incomplete biochemical changes in an
adult randomized-controlled trial.10 Biochemical differences
between groups at baseline suggest that patients with more
extensive hepatobiliary fibrosis were less likely to achieve
normalization on UDCA. There was a consistent trend across
several markers: decreased serum albumin and platelet count,
and increased APRI and bilirubin in non-normalizers.
Length of time with PSC before diagnosis is likely an
important, but ultimately unmeasurable, factor. Patient age
at diagnosis was similar in response and incomplete response
groups. We speculate that there may be additional
subphenotypes of PSC that are more slowly progressive and
more responsive to therapy, perhaps based on microbiome
or metabolome profiles.
Crohn’s disease had a negative impact on the probability of
normalization. This was in contrast to the association
between Crohn’s disease and a favorable PSC prognosis in
general. The presence of IBD overall (either ulcerative colitis
or a Crohn’s disease phenotype) is a favorable predictor of
outcome in pediatric PSC,2 and a Crohn’s disease
phenotype was a favorable predictor in adult PSC.23 Patients
with Crohn’s disease may be more likely to receive
immunomodulatory or biologic medicines than patients
with ulcerative colitis or those with no IBD, although such
medicines have not shown a survival detriment or benefit
in PSC.24,25 Differences in the microbiome of patients with
Crohn’s disease may not favor useful, disease-modifying
metabolism of UDCA in some patients. Indeed, patientsDeneau et al
- 2019 ORIGINAL ARTICLESwith PSC–Crohn’s, PSC–ulcerative colitis, and PSC with no
IBD each have distinct microbiota signatures,26 with
underrepresentation of Butyricicoccus in PSC–Crohn’s
compared with the others. The microbiome may impact for
PSC progression itself and, metabolism of and potential
responsiveness to, UDCA. Additional research is needed to
more fully characterize the relative effectiveness of medical
therapies for PSC in patients with different microbiome
profiles and across the spectrum of objectively staged
hepatobiliary fibrosis and duct stricturing.
A strength of this study was its large size and inclusion of
patients from a diverse mix of secondary and tertiary referral
centers. There are weaknesses to this study. The retrospective
design prevented a standardized diagnostic and therapeutic
algorithm, and misclassification bias may be present. We
did not have data on compliance with prescribed UDCA,
which may have been poor especially in teenage patients.
GGT and general biochemistry was only available at the
time of diagnosis and 1 year later. Data at earlier time points
to report on rapidity of GGT improvement were not
available. Similarly, longer-term data are needed to define
the durability of GGT normalization on and off chronic
UDCA therapy. Future studies should control for the severity
of intestinal disease and concomitant immunosuppression
for IBD and autoimmune hepatitis, which we were unable
to do here. Finally, objective markers of disease severity
and response are needed, including performing liver biopsy
and cholangiography before and during therapy. These data
are part of a larger, more extensive data collection that is
currently underway within the Pediatric PSC Consortium
to address these shortfalls. n
Submitted for publication Nov 16, 2018; last revision received Jan 17, 2019;
accepted Jan 18, 2019.
Reprint requests: Mark Deneau, MD, MS, Associate Professor of Pediatrics,
Division of Gastroenterology, Hepatology and Nutrition, University of Utah,
Intermountain Healthcare / Primary Children’s Hospital, 81 N. Mario Capecchi
Dr, Salt Lake City, UT 84113. E-mail: mark.deneau@hsc.utah.edu
References
1. Hirschfield GM, Karlsen TH, Lindor KD, AdamsDH. Primary sclerosing
cholangitis. Lancet 2013;382:1587-99.
2. DeneauMR, El-MataryW, Valentino PL, Abdou R, Alqoaer K, AminM,
et al. The natural history of primary sclerosing cholangitis in 781
children: a multicenter, international collaboration. Hepatology
2017;66:518-27.
3. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing
cholangitis—a comprehensive review. J Hepatol 2017;67:1298-323.
4. Dyson JK, Webb G, Hirschfield GM, Lohse A, Beuers U, Lindor K, et al.
Unmet clinical need in autoimmune liver diseases. J Hepatol 2015;62:
208-18.
5. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate
reduces hepatotoxicity of bile salts in primary human hepatocytes.
Hepatology 1990;12:486-91.
6. Stiehl A, Rudolph G, Raedsch R, M€oller B, Hopf U, Lotterer E, et al.
Ursodeoxycholic acid-induced changes of plasma and urinary bile acids
in patients with primary biliary cirrhosis. Hepatology 1990;12:492-7.
7. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I
and class II major histocompatibility complex molecules in primary
biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11:
12-5.Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing C
Normalization and Favorable Clinical Course8. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary
Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J
Med 1997;336:691-5.
9. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW.
High dose ursodeoxycholic acid for the treatment of primary sclerosing
cholangitis is safe and effective. J Hepatol 2008;48:792-800.
10. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R,
Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing
cholangitis: a 5-year multicenter, randomized, controlled study.
Gastroenterology 2005;129:1464-72.
11. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD.
High-dose ursodeoxycholic acid as a therapy for patients with primary
sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
12. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T,
Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of
primary sclerosing cholangitis. Hepatology 2009;50:808-14.
13. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B,
et al. Diagnosis and management of primary sclerosing cholangitis.
Hepatology 2010;51:660-78.
14. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of
serum alkaline phosphatase to <1.5 upper limit of normal predicts better
outcome and reduced risk of cholangiocarcinoma in primary sclerosing
cholangitis. J Hepatol 2013;58:329-34.
15. Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A.
Association between reduced levels of alkaline phosphatase and survival
times of patients with primary sclerosing cholangitis. Clin Gastroenterol
Hepatol 2013;11:841-6.
16. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD.
Alkaline phosphatase normalization is associated with better prognosis
in primary sclerosing cholangitis. Dig Liver Dis 2011;43:309-13.
17. DeneauMR,Mack C, Abdou R, AminM, Amir A, AuthM, et al. Gamma
glutamyltransferase reduction is associated with favorable outcomes in
pediatric primary sclerosing cholangitis. Hepatol Commun 2018;2:
1369-78.
18. Valentino PL, Wiggins S, Harney S, Raza R, Lee CK, Jonas MM. The
natural history of primary sclerosing cholangitis in children: a large
single-center longitudinal cohort study. J Pediatr Gastroenterol Nutr
2016;63:603-9.
19. Mayo Clinic Laboratories. Alkaline Phosphatase, Total and Isozymes,
Serum: Clinical and Interpretive, http://www.mayomedicallaboratories.
com/test-catalog/Clinical+and+Interpretive/89503. Accessed August 18,
2016.
20. Mileti E, Rosenthal P, Peters MG. Validation and modification of
simplified diagnostic criteria for autoimmune hepatitis in children.
Clin Gastroenterol Hepatol 2012;10:417-21.e1-2.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)—a metadata-driven methodology
and workflow process for providing translational research informatics
support. J Biomed Inform 2009;42:377-81.
22. Black DMC, Kerkar N, Miloh T, Sundaram S, Anand R, Gupta A, et al.
Initial results of the WUPPSC Study—Prospective Multicenter
Withdrawal of Ursodeoxycholic Acid in Pediatric Primary Sclerosing
Cholangitis [Abstract]. Gastroenterology 2018;154(6 S1):S1209.
23. Weismuller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H,
Ponsioen CY, et al. Patient age, sex, and inflammatory bowel disease
phenotype associate with course of primary sclerosing cholangitis.
Gastroenterology 2017;152:1975-84.e8.
24. Tse CS, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL. Effects of
vedolizumab, adalimumab and infliximab on biliary inflammation in
individuals with primary sclerosing cholangitis and inflammatory bowel
disease. Aliment Pharmacol Ther 2018;48:190-5.
25. Peng X, Luo X, Hou JY, Wu SY, Li LZ, Zheng MH, et al.
Immunosuppressive agents for the treatment of primary sclerosing
cholangitis: a systematic review and meta-analysis. Dig Dis 2017;35:
478-85.
26. Sabino J, Vieira-Silva S, Machiels K, JoossensM, Falony G, Ballet V, et al.
Primary sclerosing cholangitis is characterised by intestinal dysbiosis
independent from IBD. Gut 2016;65:1681-9.holangitis: Predictors of Gamma Glutamyltransferase 5
Table III. Univariate regression analysis of baseline
predictors of normalization on UDCA
Univariate OR P value
Age 0.97 .328
Sex 0.98 .941
UC 1.35 .235
Crohn’s 0.41 .026
No IBD 0.57 .094
AIH 1.01 .955
Large-duct phenotype 0.84 .586
Hemoglobin 1.15 .071
Platelet count 1.43 <.001
INR 0.82 .795
ALT 1.00 .660
AST 1.00 .710
ALP 0.99 .943
ALP 1.01 .906
GGT 0.99 .092
Total bilirubin 0.87 .005
Albumin 1.84 .008
APRI 0.95 .155
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase;
INR, international normalized ratio; UC, ulcerative colitis.
Values in bold are statistically significant.
Table IV. Multivariate model of baseline predictors of
normalization on UDCA
Multivariate OR P value
Crohn’s (vs UC or no IBD) 0.33 .012
Platelet count (per 100 000 k/mL) 1.55 <.001
GGT (per U/L) 0.99 .119
Total bilirubin (per mg/dL) 0.88 .167
Albumin (per g/dL) 1.98 .009
Values in bold are statistically significant.
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